小肾癌主动监测:活检确认队列中组织学亚型特异性生长速率
该研究在136例活检证实的cT1a肾细胞癌小肾肿物(SRMRCC)主动监测队列中比较不同组织学亚型的生长速率与进展。中位随访5.8年,透明细胞癌生长快于乳头状1型(0.25 vs 0.02 cm/年,p=0.0003),60例进展,6例转移均为透明细胞癌。结论提示生长速率因组织学亚型而异,初始随访可辅助个体化决策。
要点
- 透明细胞癌SRMs生长速率显著快于乳头状1型(0.25 vs 0.02 cm/年,p=0.0003)。
- 60例进展中82%因体积倍增,6例转移均为透明细胞癌组织学。
- 活检确认组织学亚型有助于主动监测患者的个体化随访与治疗决策。
核心结论
- SRMRCC不同组织学亚型间生长速率存在差异,透明细胞癌进展风险更高。
研究设计与样本
- 加拿大 multicenter 试验与 Princess Margaret 队列合并,纳入136例活检证实的SRMRCC主动监测病灶。
主要发现
- 透明细胞癌SRMs平均生长0.25 cm/年,乳头状1型0.02 cm/年,p=0.0003。
- 60例SRMRCC进展:49例(82%)因体积倍增,7例(12%)增至≥4 cm,4例(6.7%)同时符合两项标准。
- 6例发生转移,均为透明细胞癌组织学。
关键数值与推荐
- 进展定义为持续尺寸≥4 cm或1年内体积倍增。
- 中位随访5.8年(四分位距3.4-7.5年)针对仍在主动监测的患者。
临床怎么用
- 对活检证实的SRMs,可根据组织学亚型制定个体化主动监测随访强度。
- 透明细胞癌患者应更密切监测生长速率与进展风险。
局限性
- 使用不同影像学模态且缺乏中心影像学复核。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most reports of active surveillance (AS) of small renal masses (SRMs) lack biopsy confirmation, and therefore include benign tumors and different subtypes of renal cell carcinoma (RCC). OBJECTIVE: We compared the growth rates and progression of different histologic subtypes of RCC SRMs (SRMRCC) in the largest cohort of patients with biopsy-characterized SRMs on AS. DESIGN, SETTING, AND PARTICIPANTS: Data from patients in a multicenter Canadian trial and a Princess Margaret cohort were combined to include 136 biopsy-proven SRMRCC lesions managed by AS, with treatment deferred until progression or patient/surgeon decision. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Growth curves were estimated from serial tumor size measures. Tumor progression was defined by sustained size ≥4 cm or volume doubling within 1 yr. RESULTS AND LIMITATIONS: Median follow-up for patients who remained on AS was 5.8 yr (interquartile range 3.4-7.5 yr). Clear cell RCC SRMs (SRMccRCC) grew faster than papillary type 1 SRMs (0.25 and 0.02 cm/yr on average, respectively, p = 0.0003). Overall, 60 SRMRCC lesions progressed: 49 (82%) by rapid growth (volume doubling), seven (12%) increasing to ≥4 cm, and four (6.7%) by both criteria. Six patients developed metastases, and all were of clear cell RCC histology. Limitations include the use of different imaging modalities and a lack of central imaging review. CONCLUSIONS: Tumor growth varies between histologic subtypes of SRMRCC and among SRMccRCC, which likely reflects individual host and tumor biology. Without validated biomarkers that predict this variation, initial follow-up of histologically characterized SRMs can inform personalized treatment for patients on AS. PATIENT SUMMARY: Many small kidney cancers are suitable for surveillance and can be monitored over time for change. We demonstrate that different types of kidney cancers grow at different rates and are at different risks of progression. These results may guide better personalized treatment.
引用
- Finelli A, Cheung DC, Al-Matar A, et al. Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. Eur Urol. 2020. PMID: 32680677. doi:10.1016/j.eururo.2020.06.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。